Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. (RXRX) Stock Overview

Explore Recursion Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

RXRX●NASDAQ
HealthcareBiotechnology
$3.56
$0.31(9.54%)
U.S. Market opens in 13h 26m

Recursion Pharmaceuticals, Inc. (RXRX)

Meyka AI Score

Z

Key Financials

Market Cap1.9B
P/E Ratio-3.43
EPS (TTM)$-1.04
ROE-0.50%
Fundamental Analysis

AI Price Forecasts

1 Month$2.47
3 Months$2.46
1 Year Target$3.17

RXRX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Recursion Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RXRX on the NASDAQ shows an RSI of 58.48, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $3.17 for the NASDAQ listing.

Key metrics behind Recursion Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -3.43 and a market capitalization of 1.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RXRX on the NASDAQ.

Price Performance (NASDAQ: RXRX)

1-Day Change
9.54%
5-Day Change
4.71%
1-Month Change
20.27%
3-Month Change
19.87%
6-Month Change
-5.57%
Year-to-Date (YTD) Change
-12.96%
1-Year Change
-26.29%
3-Year Change
-58.26%
5-Year Change
-83.82%
All-Time (Max) Change
-80.22%

Contact Information

https://www.recursion.com
385 269 0203
41 South Rio Grande Street, Salt Lake City, UT, 84101

Company Facts

6,000 Employees
IPO DateApr 16, 2021
CountryUS
Actively Trading

Frequently Asked Questions